1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
PELL Bio-Med Technology Co Ltd

PELL Bio-Med Technology Co Ltd

TTWSE:6949
37.70
TWD
-1.40
(-3.58%)
2.85BMarket Cap
PELL Bio-Med Technology Co Ltd
TWSE:6949
(Taiwan Stock Exchange)

Recent

price

37.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
TWD
0.42
0.43
0.39
0.34
0.54
- -
Revenue per Share
-5.63
-5.82
-8.55
-6.83
-7.23
- -
Basic EPS, GAAP
-3.65
-4.29
-4.21
-9.19
-8.68
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
3.9
13.9
20.31
20.24
23.99
39.24
Book Value per Share
3.88
13.86
20.27
20.21
23.94
38.93
Tangible Book Value per Share
34
40
47
57
59
341
Basic Weighted Avg Shares
14
17
18
20
31
- -
Sales/Revenue/Turnover
-1,402.03
-1,375.79
-2,280.52
-2,106.35
-1,487.24
- -
Operating Margin (%)
30
31
46
47
47
- -
Depreciation Expense
-189
-230
-399
-389
-424
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1,351.93
-1,341.32
-2,211.26
-1,983.67
-1,349.09
- -
Profit Margin (%)
88
668
1,038
836
1,022
2,107
Working Capital
125
173
147
137
109
101
LT Debt
225
815
1,181
1,286
1,694
2,822
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-44.87
-40.46
-33.14
-32.59
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
128
130
130
LT Borrowings
- -
- -
- -
LT Finance Leases
109
109
101
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
59
65
66
Market Capitalization
1,015
1,820
2,855

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,331
2,495
2,339
Cash, Cash Equivalents & STI
1,311
2,449
2,269
Accounts Receivable, Net
5
6
8
Inventories
7
13
19
Total Current Liabilities
309
260
232
Payables & Accruals
- -
- -
- -
ST Debt
128
130
130
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
31.7%
Free Cash Flow
- -
- -
-2.9%
Net Income, GAAP
- -
- -
8.87%
Sales/Revenue/Turnover
- -
- -
60.07%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5
5
5
5
20
2025
12
6
- -
6
31
2026
6
9
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.54
-1.76
-1.75
-0.09
-6.83
2025
-1.3
-1.33
- -
-0.13
-7.23
2026
-1.18
-1.36
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Pell Bio-Med Technology Co., Ltd. (6949.TW) develops cell culture technologies and techniques for therapeutic applications in the biotechnology sector, focusing on immune cell therapies and regenerative medicine; its core products and services include good tissue practice (GTP) laboratory infrastructure, adipose-derived stem cells (ADSC) for regenerative treatments such as degenerative joint conditions and aesthetic tissue filling, cytokine-induced killer (CIK) cells and dendritic cell-CIK (DC-CIK) therapies against cancers, chimeric antigen receptor T-cell (CAR-T), CAR-NK, and CAR-γδT immunotherapies, along with gene-modified ADSC and pipeline candidates targeting B-cell non-Hodgkin lymphoma (B-NHL), ovarian cancer, multiple myeloma, and thyroid cancer. Founded in 2017 and headquartered at No. 87, Xinhu 2nd Road, 4th Floor, Neihu District, Taipei, Taiwan, the company operates primarily in Taiwan with clinical applications centered on autologous T-cell therapies and stem cell regeneration for oncology and orthopedic patients. In recent developments, Pell Bio-Med Technology completed its initial public offering (IPO) on the Taiwan Stock Exchange's Taiwan Innovation Board in March 2024, marking a significant capital-raising milestone to advance its CAR-T product PL001 for B-cell lymphoma and other immune genetic engineering programs; it continues to report quarterly earnings, with third quarter 2025 results showing ongoing R&D investments amid revenue growth to NT$26.58 million (TTM) while advancing non-genetically modified immune cell treatments.